Monotherapy with a P2Y12 receptor inhibitor followed by direct oral anticoagulant therapy in patients with atrial fibrillation undergoing coronary angioplasty with supraflex cross stent implantation.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: INSEL GRUPPE AG
- Phase: III
- Execution start: 19/03/2025
- End of execution: 30/12/2027
- IP: JUAN CABALLERO BORREGO
